Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances

被引：0

作者：

Lessans, Spencer ^{[1
]}

O'Connell, Katie A. ^{[2
]}

Choe, Jennifer ^{[3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Internal Med, Nashville, TN USA

[2] Vanderbilt Univ, Med Ctr, Dept Dermatol, Nashville, TN USA

[3] Vanderbilt Univ, Dept Hematol Oncol, Med Ctr, Preston Res Bldg 790,2220 Pierce Ave, Nashville, TN 37232 USA

来源：

CURRENT ONCOLOGY REPORTS | 2024年 / 26卷 / 09期

基金：

英国科研创新办公室;

关键词：

Squamous cell carcinoma; Basal cell carcinoma; Merkel cell carcinoma; Immunotherapy; Neoadjuvant; SQUAMOUS-CELL CARCINOMA; BASAL-CELL; HEDGEHOG PATHWAY; OPEN-LABEL; PHASE-II; TRANSPLANT RECIPIENTS; INHIBITOR; PEMBROLIZUMAB; POLYOMAVIRUS; CHEMOTHERAPY;

D O I：

10.1007/s11912-024-01570-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of ReviewThis review provides an update on approved and emerging systemic therapies in the treatment of locally advanced or metastatic non-melanoma skin cancers (squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma).Recent FindingsMany studies demonstrate the effectiveness of immunotherapy for all types of non-melanoma skin cancer. For basal cell carcinoma (BCC), hedgehog inhibitors (HHI) remain first-line but with poor tolerability. Numerous clinical trials studying both neoadjuvant and adjuvant use of anti-PD-1 and anti-PD-L1 therapies in advanced NMSC are under investigation.SummaryThere is a growing number of systemic therapies available to treat non-melanoma skin cancers. The advent of immunotherapy has revolutionized the field and greatly improved survival compared to historical survival rates with cytotoxic chemotherapy.

引用

页码：1120 / 1133

页数：14

共 112 条

[1]

4SC AG, 2023, PHASE 2 OPEN LABEL S

[2] High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma [J].

Akaike, T. ;

Qazi, J. ;

Anderson, A. ;

Behnia, F. S. ;

Shinohara, M. M. ;

Akaike, G. ;

Hippe, D. S. ;

Thomas, H. ;

Takagishi, S. R. ;

Lachance, K. ;

Park, S. Y. ;

Tarabadkar, E. S. ;

Iyer, J. G. ;

Blom, A. ;

Parvathaneni, U. ;

Vesselle, H. ;

Nghiem, P. ;

Bhatia, S. .

BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (02) :319-327

[3] Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives [J].

Alberti, Andrea ;

Bossi, Paolo .

FRONTIERS IN ONCOLOGY, 2022, 11

[4] Merkel cell carcinoma: Prognosis and treatment of patients from a single institution [J].

Allen, PJ ;

Bowne, WB ;

Jaques, DP ;

Brennan, MF ;

Busam, K ;

Coit, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2300-2309

[5] A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors [J].

Amin, Manik ;

Minton, Susan E. ;

LoRusso, Patricia M. ;

Krishnamurthi, Smitha S. ;

Pickett, Cheryl A. ;

Lunceford, Jared ;

Hille, Darcy ;

Mauro, David ;

Stein, Mark N. ;

Wang-Gillam, Andrea ;

Trull, Lauren ;

Lockhart, A. Craig .

INVESTIGATIONAL NEW DRUGS, 2016, 34 (01) :84-95

[6]

Anderson A., 2015, J CLIN ONCOL, V33, pe20031, DOI [10.1200/jco.2015.33.15suppl.e20031, DOI 10.1200/JCO.2015.33.15SUPPL.E20031]

[7] Smoothened Regulation: A Tale of Two Signals [J].

Arensdorf, Angela M. ;

Marada, Suresh ;

Ogden, Stacey K. .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (01) :62-72

[8] Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (12)

[9] Avelumab: a new standard for treating metastatic Merkel cell carcinoma [J].

Baker, Mairead ;

Cordes, Lisa ;

Brownell, Isaac .

EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (04) :319-326

[10]

Bauer Michael, 2021, Crit Care Explor, V3, pe0577, DOI 10.1097/CCE.0000000000000577

← 1 2 3 4 5 6 7 8 9 10 →